GENE logo.png
GTG to form Strategic Alliance with global testing leader QIAGEN
01. Februar 2023 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
Cash Receipts
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
30. Januar 2023 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health,...
GENE logo.png
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
24. Januar 2023 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...
GENE logo.png
Genetic Technologies Provides Business Update
11. Januar 2023 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
GENE logo.png
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes
06. Dezember 2022 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
GENE logo.png
Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease
10. November 2022 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease...
GENE logo.png
Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention
09. November 2022 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health,...
GENE logo.png
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details
25. Oktober 2022 09:14 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
GENE logo.png
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer
29. September 2022 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...
GENE logo.png
Genetic Technologies Provides Update on US Operations and Payer Engagement
02. September 2022 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in...